Highest exposure to styrene | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Background | Low/moderate | High <1 year | High ≥1 year | |||||||||||
Cancer | Cases | Controls | Cases | Controls | OR | 95% CI | Cases | Controls | OR | 95% CI | Cases | Controls | OR | 95% CI |
Hodgkin's disease | 3 | 27 | 2 | 11 | 1.50 | 0.17 to 13.56 | 1 | 21 | 0.39 | 0.03 to 5.09 | 1 | 11 | 0.74 | 0.06 to 9.94 |
Non-Hodgkin's lymphoma (including chronic lymphocytic leukaemia) | 26 | 175 | 14 | 166 | 0.53 | 0.24 to 1.15 | 18 | 187 | 0.61 | 0.30 to 1.25 | 11 | 118 | 0.54 | 0.23 to 1.27 |
Multiple myeloma | 6 | 76 | 7 | 63 | 2.15 | 0.51 to 9.12 | 6 | 41 | 2.66 | 0.67 to 10.64 | 5 | 35 | 2.66 | 0.62 to 11.35 |
Other leukaemia | 8 | 59 | 5 | 57 | 0.60 | 0.13 to 2.79 | 6 | 56 | 0.84 | 0.23 to 3.02 | 3 | 35 | 0.62 | 0.13 to 3.03 |
All lymphatic and haematopoietic cancer | 43 | 337 | 28 | 297 | 0.73 | 0.40 to 1.33 | 31 | 305 | 0.81 | 0.47 to 1.41 | 20 | 199 | 0.76 | 0.40 to 1.44 |
All risk estimates are relative to background exposure, and relate to exposure status 5 years before the case (for controls, the matched case) was first known to have been diagnosed.